Schedule 13D ownership disclosure

BRIDGEBIO PHARMA INC

Security class unavailable · CUSIP: 10806X102

Event date: 2019-06-27

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
26,620,991
Percent of class
22.1000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000903423-19-000277
Form type
SC 13D
Filer
BridgeBio Pharma, Inc.
CIK
CIK 1743881
Filed
Jul 08, 2019
Reporting period
Jun 27, 2019
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub